Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets assoc ...

-  EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)-  Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system-  FL is considered incurable with current standard of care therapies. Many people living with FL who have relapsed or are refractory to existing therapies have limited treatment options and reduced survival1NORTH CHICAGO, ...

AbbVie (ABBV) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). This is the second CRL issued for ABBV-951 by the FDA.The latest CRL was based on some observations on inspection of one of AbbVie's third-party manufacturing facilities listed in the NDA. The inspection did not involve ABBV-951 or any other AbbVie drug. The FDA has not requ ...

The most recent trading session ended with AbbVie (ABBV) standing at $170.75, reflecting a -1.15% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.09%. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Heading into today, shares of the drugmaker had gained 9.98% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.Investors will be eagerly watching for the per ...

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufacturing facilitiesThe CRL does not identify any issues related to the safety, efficacy or labeling of ABBV-951, including the device, and does not request that AbbVie conduct additional efficacy or safety trials related to the drug or device-related testingAbbVie continues to work with the FDA to bring ABBV-951 ...

Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (ABBV 1.38%), Ares Capital (ARCC 0.44%), and Realty Income (O 0.92%) have what it takes to deliver heaps of dividend payments to your portfolio in the years ahead.Whether you're interested in a high yield up front, rapid payout growth, or a litt ...

With the stock market near all-time highs, I’m looking forward to the next market crash. Yes, I want the stock market to fall and fall hard. Why? Because that is when you can go on a shopping spree. All the great companies that are trading at exceptionally high premiums will be suddenly offering discounts. That is when you want to buy.The last market crash was brought on by the pandemic. The S&P 500 lost one-third of its value in just one month. Ouch! Since then, though, the benchmark index has been nothing ...

文章核心观点 - 生物科技行业增长放缓,重点转向慢性疾病如糖尿病、癌症和心脏病的治疗[1][2] - 主要生物科技公司正在开发针对长期患者的治疗方案,成为投资者关注的焦点[2] 公司分析 AbbVie (ABBV) - 最近获得FDA批准的溃疡性结肠炎药物Skyrizi,可能也能治疗克罗恩病[4][5] - 考虑到每100名美国人就有1人患有肠道疾病,ABBV的药物销售前景良好[5] Novo Nordisk (NVO) - 计划在北卡罗来纳州扩大11亿美元的制造能力,以满足其减肥和糖尿病药物的需求[6] - 第一季度收入增长22.4%,净利润增长28.2%,现金储备增加有利于进一步扩张[7] Eli Lilly (LLY) - 其糖尿病和减肥药物Mounjaro和Zepbound销售良好,推动收入同比增长[7] - 新的阿尔茨海默病药物Donanemab获FDA批准,为公司开辟了新的市场[8] - 针对美国670万阿尔茨海默病患者的药物有望为公司带来重大影响[8][9]

文章核心观点 - 艾伯维公司董事会宣布每股1.55美元的季度现金股息，自2013年成立以来股息增长超285%，是标准普尔股息贵族指数成分股 [1] 公司动态 - 公司董事会宣布每股1.55美元的季度现金股息 [1] - 现金股息将于2024年8月15日支付给2024年7月15日收盘时登记在册的股东 [1] - 自2013年公司成立以来，股息增长超285% [1] - 公司是标准普尔股息贵族指数成分股，该指数追踪连续至少25年每年提高股息的公司 [1] 公司介绍 - 公司使命是发现并提供创新药物和解决方案，解决当前严重健康问题并应对未来医疗挑战 [2] - 公司致力于在免疫学、肿瘤学、神经科学和眼科等关键治疗领域以及艾尔建美学产品组合中对人们生活产生显著影响 [2] - 可访问www.abbvie.com了解公司更多信息，也可在领英、脸书、照片墙、X（原推特）和YouTube上关注公司 [2]

Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent directorNORTH CHICAGO, Ill., June 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve on the AbbVie Board as an independent director."One of AbbVie's great ...